|1.||Renda, Chiara: 1 article (01/2009)|
|2.||Di Raimondo, Domenico: 1 article (01/2009)|
|3.||Tuttolomondo, Antonino: 1 article (01/2009)|
|4.||Pinto, Antonio: 1 article (01/2009)|
|5.||Di Sciacca, Riccardo: 1 article (01/2009)|
|6.||Licata, Giuseppe: 1 article (01/2009)|
|7.||Goodwin, Cleon W: 1 article (05/2003)|
|8.||Hunt, John L: 1 article (05/2003)|
|9.||Yurt, Roger W: 1 article (05/2003)|
|10.||Saffle, Jeffrey R: 1 article (05/2003)|
10/23/2001 - "The authors conclude that anti-ICAM therapy with enlimomab is not an effective treatment for ischemic stroke in the model studied and, indeed, may significantly worsen stroke outcome."
01/01/2009 - "Treatment with a murine anti-ICAM-1 antibody (enlimomab) has been investigated in patients with acute ischemic stroke in the Enlimomab Acute Stroke Trial (EAST). "
11/01/2001 - "Enlimomab, a murine monoclonal anti-human intercellular adhesion molecule (ICAM)-1 antibody, had a negative outcome in a multicenter acute-stroke trial. "
10/23/2001 - "Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial."
09/01/1998 - "However, this treatment failed to show benefit in the Enlimomab Acute Stroke Trial. "
|4.||Wounds and Injuries (Trauma)
08/01/1998 - "A loading dose of enlimomab administered within 24 h of the onset of stroke symptoms was followed by four daily maintenance doses; total doses ranged from 140 to 480 mg. The pharmacokinetic target levels (enlimomab serum levels of >/=10 microg/ml) were consistently achieved in all patients receiving dose regimens III and IV. Non-serious adverse events thought to be causally related to enlimomab administration included headache, vomiting and extrasystoles. "
|1.||Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
|1.||Homologous Transplantation (Allograft)